MLYS
Income statement / Annual
Last year (2023), Mineralys Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Mineralys Therapeutics, Inc.'s net income was -$71.90 M.
See Mineralys Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$70.36 M
|
$26.25 M
|
$16.31 M
|
$2.41 M
|
| General & Administrative
Expenses |
$14.30 M
|
$5.23 M
|
$2.42 M
|
$532,000.00
|
| Selling & Marketing
Expenses |
$14.28 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$14.30 M
|
$5.23 M
|
$2.42 M
|
$532,000.00
|
| Other Expenses |
$0.00 |
$4,000.00 |
$1,000.00 |
-$1,000.00 |
| Operating Expenses |
$84.66 M |
$31.48 M |
$18.73 M |
$2.94 M |
| Cost And Expenses |
$84.66 M |
$31.48 M |
$18.73 M |
$2.94 M |
| Interest Income |
$12.76 M |
$1.68 M |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$1.68 M |
$27,000.00 |
$115,000.00 |
| Depreciation &
Amortization |
$167,895.00
|
$228,485.00
|
$18.73 M
|
$2.94 M
|
| EBITDA |
-$84.66 M
|
-$31.48 M
|
-$18.72 M
|
-$2.94 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$12.76 M
|
$4,000.00
|
-$656,000.00
|
-$368,000.00
|
| Income Before Tax |
-$71.90 M |
-$29.80 M |
-$19.41 M |
-$3.43 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$167,895.00 |
-$1.90 M |
$27,000.00 |
$115,000.00 |
| Net Income |
-$71.90 M |
-$29.80 M |
-$19.41 M |
-$3.43 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
| EPS |
-1.99 |
-0.73 |
-0.5 |
-0.0877 |
| EPS Diluted |
-1.99 |
-0.73 |
-0.5 |
-0.0877 |
| Weighted Average Shares
Out |
$36.19 M
|
$40.86 M
|
$39.06 M
|
$39.06 M
|
| Weighted Average Shares
Out Diluted |
$36.19 M
|
$40.86 M
|
$39.06 M
|
$39.06 M
|
| Link |
|
|
|
|
